Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.
M J Weinstein, L E Chute
M J Weinstein, L E Chute
Published February 1, 1984
Citation Information: J Clin Invest. 1984;73(2):307-316. https://doi.org/10.1172/JCI111215.
View: Text | PDF
Research Article

Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

  • Text
  • PDF
Abstract

We have characterized Factor VIII coagulant protein, present in normal human plasma, that reacts with a specific human 125I-labeled anti-human VIII:C antigen Fab antibody fragment. Two major Factor VIII coagulant antigen populations were present. The first, approximately 85% of the total antigen, was bound to von Willebrand factor and when tested in a standard one-stage assay had Factor VIII coagulant activity. The second antigenic population, eluting near fibrinogen when plasma was gel filtered, was not bound to von Willebrand protein, did not have Factor VIII coagulant activity unless activated, but did block anti-VIII:C Fab neutralization of clotting activity. The two antigenic populations were separable by cryoprecipitation and agarose gel electrophoresis. Although the two antigenic populations differed in their Factor VIII coagulant activity and in their binding to von Willebrand factor, the principal member of both populations is of mol wt 2.4 X 10(5). Both antigens, when proteolyzed by thrombin, were quickly converted to a 1 X 10(5)-mol wt form in association with the appearance of VIII:C activity. The 1 X 10(5)-mol wt antigen was further slowly degraded to an 8 X 10(4)-mol wt form while Factor VIII coagulant activity declined. These results demonstrate the presence of an inactive Factor VIII coagulant protein in plasma, not associated with von Willebrand factor, that can react with thrombin to yield Factor VIII coagulant activity.

Authors

M J Weinstein, L E Chute

×

Total citations by year

Year: 2020 2011 1992 1990 1988 1987 1986 1985 1983 Total
Citations: 1 1 1 2 1 1 4 2 1 14
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (14)

Title and authors Publication Year
FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys
S Pestel, HW Beltz, P Claar, H Lind, M Mischnik, E Raquet, A Andrews, J Simmonds, V Tomasetig, SK Dower, A Tjärnlund-Wolf, S Schulte, PM Schmidt, T Weimer
Blood Advances 2020
Von Willebrand Disease
PM Mannucci, M Franchini
Von Willebrand Disease 2011
Further evidence for recessive inheritance of von willebrand disease with abnormal binding of von willebrand factor to factor VIII
MF Lopez-Fernandez, MJ Blanco-Lopez, MP Castiñeira, J Batlle
American Journal of Hematology 1992
Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis
MW Mosesson, DN Fass, P Lollar, JP DiOrio, CG Parker, GJ Knutson, JF Hainfeld, JS Wall
Journal of Clinical Investigation 1990
New Trends in Haemostasis
J Harenberg, DL Heene, G Stehle, G Schettler
1990
Subunit structure of thrombin-activated human factor VIIIa
PJ Fay
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 1988
Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors)
LW Hoyer
Human Pathology 1987
Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor
P Bockenstedt, JM Greenberg, RI Handin
Journal of Clinical Investigation 1986
The physiology and pathophysiology of the factor VIII complex
RJ Hamer, WP Houdijk, JJ Sixma, TW Barrowcliffe
Critical Reviews in Oncology/Hematology 1986
The size of human factor VIII heterodimers and the effects produced by thrombin
PJ Fay, MT Anderson, SI Chavin, VJ Marder
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 1986
Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling
RJ Hamer, JA Koedam, NH Beeser-Visser, JJ Sixma
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 1986
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation
MJ Weinstein, LE Chute, GW Schmitt, RH Hamburger, KA Bauer, JH Troll, P Janson, D Deykin
Journal of Clinical Investigation 1985
Immunology of Rheumatic Diseases
S Gupta, N Talal
1985
New Comprehensive Biochemistry
S Yamamoto
New Comprehensive Biochemistry 1983

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts